|Focus on Induction Regimens for Transplant-eligible Patients with Multiple Myeloma|
Sergio A. Giralt, MD, FACP
|Release Date: May 23, 2018|
Expiration Date: May 23, 2019
Despite exciting new developments in the number and kind of pharmacologic options available for multiple myeloma (MM), stem cell transplantation remains an important first-line treatment that is often underutilized. This activity will address critical factors that must be considered when making treatment decisions concerning transplant in MM patients, including safety, efficacy, and potential for long-term remission.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
|Begin, Earn CreditView Only, No Credit|